Moonwalk Biosciences
Moonwalk Biosciences is a biotechnology company focused on pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic insights. They leverage their discovery platform to identify new targets related to obesity and cardiometabolic diseases. The company is advancing an early-stage pipeline of therapeutic candidates, with a strong emphasis on epigenome engineering as the next frontier in genetic medicines to create safer and more effective treatments. Their approach aims to move cellular states back toward health.
Moonwalk Biosciences
Moonwalk Biosciences is a biotechnology company focused on pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic insights. They leverage their discovery platform to identify new targets related to obesity and cardiometabolic diseases. The company is advancing an early-stage pipeline of therapeutic candidates, with a strong emphasis on epigenome engineering as the next frontier in genetic medicines to create safer and more effective treatments. Their approach aims to move cellular states back toward health.
TL;DR
Stage: Early-stage (Seed & Series A announced)
Focus: Precision epigenetic medicines (EpiRead & EpiWrite platforms)
Founded: 2022
Notable backers: Alpha Wave Ventures, ARCH, GV, Khosla, Future Ventures, YK Bioventures
Company Overview
Problem Domain
Obesity and cardiometabolic disease therapeutics; epigenetic modulation of cellular states.
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
57000000
Round announced at company launch; participating investors include ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures.
Investor Signal
“Led by Alpha Wave Ventures with participation from ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures”